Skip to main content

Mobic® offers osteoarthritis and rheumatoid arthritis patients an alternative treatment option

Pressmeddelande   •   Okt 01, 2004 13:06 CEST

Mobic® offers osteoarthritis and rheumatoid arthritis patients an alternative treatment option
Patients are encouraged to work with their physicians to discuss treatment alternatives

- With the announcement by Merck & Co. yesterday, recalling one of the most commonly prescribed arthritis medications Vioxx® due to cardiac side-effects, millions of arthritis patients worldwide will be working with their healthcare providers to re-evaluate their treatment.

Boehringer Ingelheim confirms that this news is not related to meloxicam (Mobic®). Mobic® is a nonsteroidal anti-inflammatory drug (NSAID), and is a selective COX-2 inhibitor, indicated for the symptomatic treatment of painful osteoarthritis, rheumatoid arthritis and ankylosing spondylitis (indications depend on local registrations). Differences in the profiles of meloxicam over other selective COX-2 inhibitors are explained by the fact that meloxicam is structurally different from other COX-2 inhibitors and works by exploiting a greater degree of flexibility at the apex of the COX-2 channel. Mobic® has been used by more than 70 million patients in 100 countries worldwide since first introductions in 1995.

The low overall, gastrointestinal and cardiovascular risk of adverse events was confirmed in a meta-analysis of 48 clinical and observational studies of 117,755 patients treated with meloxicam and traditional painkillers. This analysis demonstrated a favourable GI risk profile for meloxicam with no indication of excess risk in overall, cardiovascular, renal and hepatic toxicity compared to non-COX-2 selective NSAIDS.

“Patients may be concerned by the withdrawal of a drug they have been using for some time because of a painful condition. We are sorry that the withdrawal was necessary, but would like to reassure patients that there are alternatives available such as Mobic®, which continues to be a treatment option for millions of osteoarthritis and rheumatoid arthritis patients worldwide,” said Dr. Andreas Barner, Member of the Board of Managing Directors at Boehringer Ingelheim, responsible for Research, Development and Medicine. “In light of the recent news, patients should work with their physicians to discuss treatment options in their arthritis therapy.”

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 152 affiliates in 45 countries and more than 34,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2003, Boehringer Ingelheim posted net sales of 7.4 billion euro while spending more than one fifth of net sales in its largest business segment Prescription Medicines on research and development.

Boehringer Ingelheim GmbH
Corporate Division Communications
Judith von Gordon
55216 Ingelheim am Rhein
Phone: +49/6132/77 35 82
Fax: +49/6132/77 66 01